{"brief_title": "Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program", "brief_summary": "The purpose of this clinical research study is to provide entecavir to subjects with chronic Hepatitis B infection who have failed or who have demonstrated intolerance of marketed therapies or for those in whom use of these agents is contraindicated and that have no other available treatment options.", "condition": "Chronic Disease", "intervention_type": "Drug", "intervention_name": "Entecavir", "description": "Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.", "other_name": "Baraclude", "criteria": "Inclusion Criteria: - Hepatitis B Early Access Program", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00096811.xml"}